| Year |
Citation |
Score |
| 2023 |
Liu Z, Zhou J, Yang X, Liu Y, Zou C, Lv W, Chen C, Cheng KK, Chen T, Chang LJ, Wu D, Mao J. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Molecular Cancer. 22: 3. PMID 36617554 DOI: 10.1186/s12943-022-01711-9 |
0.337 |
|
| 2022 |
Han S, Zhou L, Chen Y, Zhou X, Guo Z, Yang J, Jin B, Liu Y, Chang LJ, Li Y, Tu S. The role of allogeneic haematopoietic cell transplantation as consolidation after anti-CD19 CAR-T cell therapy in adults with relapsed/refractory acute lymphoblastic leukaemia: a prospective cohort study. Bone Marrow Transplantation. PMID 35058582 DOI: 10.1038/s41409-022-01572-2 |
0.364 |
|
| 2021 |
Yu L, Huang L, Lin D, Lai X, Wu L, Liao X, Liu J, Zeng Y, Liang L, Zhang G, Wang B, Wu Z, Tao S, Liu Y, Jiao C, ... Chang LJ, et al. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients. Journal of Cancer Research and Clinical Oncology. PMID 34724115 DOI: 10.1007/s00432-021-03839-5 |
0.312 |
|
| 2021 |
Chang CW, Liu Y, Jiao C, Liu H, Gong J, Chen X, Chang LJ. A Glimpse into the Diverse Cellular Immunity against SARS-CoV-2. Vaccines. 9. PMID 34451952 DOI: 10.3390/vaccines9080827 |
0.318 |
|
| 2021 |
Xie L, Ma L, Liu S, Chang L, Wen F. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia. International Immunopharmacology. 96: 107731. PMID 33965880 DOI: 10.1016/j.intimp.2021.107731 |
0.422 |
|
| 2020 |
Zhou X, Tu S, Wang C, Huang R, Deng L, Song C, Yue C, He Y, Yang J, Liang Z, Wu A, Li M, Zhou W, Du J, Guo Z, ... ... Chang LJ, et al. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Frontiers in Immunology. 11: 564099. PMID 33329526 DOI: 10.3389/fimmu.2020.564099 |
0.401 |
|
| 2020 |
Sujjitjoon J, Sayour E, Tsao ST, Uiprasertkul M, Sanpakit K, Buaboonnam J, Yenchitsomanus PT, Atchaneeyasakul LO, Chang LJ. GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction. Translational Oncology. 14: 100971. PMID 33321428 DOI: 10.1016/j.tranon.2020.100971 |
0.402 |
|
| 2020 |
Xu X, Zhao W, Yue Z, Qin M, Jin M, Chang LJ, Ma X. 4SCAR-GD2-modified T-cell therapy in neuroblastoma with amplification: A case report with over 4-year follow-up data. Pediatric Investigation. 4: 55-58. PMID 32851343 DOI: 10.1002/ped4.12181 |
0.319 |
|
| 2020 |
Lai X, Sun YY, Chang LJ, Ma YR, Gu XZ, Yao XM, Nie B, Wen Y, Zhang XM, Jiang YX, Yang H, Yu LQ, Fang MJ, Wang L, Yuan Bo X. Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy? Bioengineered. 11: 824-828. PMID 32772769 DOI: 10.1080/21655979.2020.1791597 |
0.384 |
|
| 2020 |
Zhang H, Gan WT, Hao WG, Wang PF, Li ZY, Chang LJ. Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia. Frontiers in Oncology. 10: 685. PMID 32528876 DOI: 10.3389/Fonc.2020.00685 |
0.439 |
|
| 2020 |
Chulanetra M, Morchang A, Sayour E, Eldjerou L, Milner R, Lagmay J, Cascio M, Stover B, Slayton W, Chaicumpa W, Yenchitsomanus PT, Chang LJ. GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas. American Journal of Cancer Research. 10: 674-687. PMID 32195035 |
0.385 |
|
| 2019 |
Tu S, Zhou X, Guo Z, Huang R, Yue C, He Y, Li M, Chen Y, Liu Y, Chang LJ, Li Y. CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma. Frontiers in Oncology. 9: 1350. PMID 31867275 DOI: 10.3389/Fonc.2019.01350 |
0.505 |
|
| 2019 |
Tu S, Huang R, Guo Z, Deng L, Song C, Zhou X, Yue C, Zhang L, He Y, Yang J, Liang Z, Du J, Cao P, Li Y, Chang LJ, et al. Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CRES or severe CRS. American Journal of Hematology. PMID 31489688 DOI: 10.1002/Ajh.25630 |
0.44 |
|
| 2019 |
Zuo YX, Jia YP, Wu J, Wang JB, Lu AD, Dong LJ, Chang LJ, Zhang LP. [Chimeric antigen receptors T cells for treatment of 48 relapsed or refractory acute lymphoblastic leukemia children: long term follow-up outcomes]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi. 40: 270-275. PMID 31104436 DOI: 10.3760/Cma.J.Issn.0253-2727.2019.04.002 |
0.463 |
|
| 2018 |
Nair S, Wang JB, Tsao ST, Liu Y, Zhu W, Slayton WB, Moreb JS, Dong L, Chang LJ. Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling. Current Gene Therapy. PMID 30444200 DOI: 10.2174/1566523218666181116093857 |
0.478 |
|
| 2018 |
Zhang JP, Zhang R, Tsao ST, Liu YC, Chen X, Lu DP, Castillo P, Chang LJ. Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient. Blood Advances. 2: 1691-1695. PMID 30026294 DOI: 10.1182/Bloodadvances.2018017004 |
0.421 |
|
| 2018 |
Park YP, Jin L, Bennett KB, Wang D, Fredenburg KM, Tseng JE, Chang LJ, Huang J, Chan EKL. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma. Oral Oncology. 78: 145-150. PMID 29496042 DOI: 10.1016/J.Oraloncology.2018.01.024 |
0.411 |
|
| 2018 |
Tu S, Huang R, Deng L, Zhou X, He Y, Zhou W, Yang J, Yue C, Wu A, Li M, Guo Z, Chang L, Li Y. Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia Blood. 132: 2696-2696. DOI: 10.1182/Blood-2018-99-118928 |
0.393 |
|
| 2018 |
Tu S, Deng L, Huang R, Zhou X, Yang J, Zhou W, Li M, Yue C, Wu S, Guo Z, Chang L, Li Y. A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Blood. 132: 4015-4015. DOI: 10.1182/Blood-2018-99-118526 |
0.489 |
|
| 2018 |
Tu S, Huang R, Zhou X, He Y, Liang Z, Wang L, Chang L, Li Y. Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma Blood. 132: 5389-5389. DOI: 10.1182/Blood-2018-99-117694 |
0.438 |
|
| 2018 |
Chang L, Li Y, Tu S, Lai X, Huang R, Tsao S, Liu Y, Zhang R, Deng L, Zhou X, Zhang H, Zhang W, Li Y. Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas Blood. 132: 225-225. DOI: 10.1182/Blood-2018-99-114396 |
0.432 |
|
| 2017 |
Hao L, Li T, Chang LJ, Chen X. Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T-cells: A systematic review of efficacy and safety. Current Medicinal Chemistry. PMID 28762313 DOI: 10.2174/0929867324666170801101842 |
0.37 |
|
| 2017 |
Lai X, Gu X, Tsao S, Zhang Q, Liu Y, Yaxian J, Yan L, Chun J, Zhang R, Du Y, Gao X, Yang Y, Qiu X, Fang M, Wei S, ... Chang L, et al. Double CD19/CD22 Chimeric Antigen Receptor-Modified T Cells for the Treatment of Stage IV Relapsed and Refractory Follicular Lymphoma Blood. 130: 5154-5154. DOI: 10.1182/Blood.V130.Suppl_1.5154.5154 |
0.429 |
|
| 2017 |
Yang L, Ma X, Liu Y, Zhao W, Yu L, Qin M, Zhu G, Wang K, Shi X, Zhang Z, Wang J, Sun Y, Dong L, Tsao S, Zhang R, ... Chang L, et al. Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China Blood. 130: 3335-3335. DOI: 10.1182/Blood.V130.Suppl_1.3335.3335 |
0.359 |
|
| 2017 |
Nishio N, Wang K, Narita K, Kataoka S, Kitazawa H, Hamada M, Ichikawa D, Taniguchi R, Murakami N, Kojima D, Suzuki K, Kawashima N, Nishikawa E, Okuno Y, Narita A, ... ... Chang L, et al. Durable Remission after Salvage Chemotherapy with Combining Bortezomib and Vorinostat Followed By CD19 CAR-T Therapy in a Patient with MLL-Rearranged ALL after Early Relapse Post Allogeneic Hematopoietic Stem Cell Transplantation Blood. 130: 3334-3334. DOI: 10.1182/Blood.V130.Suppl_1.3334.3334 |
0.441 |
|
| 2016 |
Li H, Chang LJ, Neubauer DR, Muir DF, Wallace MR. Immortalization of human normal and NF1 neurofibroma Schwann cells. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 27617404 DOI: 10.1038/Labinvest.2016.88 |
0.351 |
|
| 2016 |
Zuo YX, Wang JB, Lu AD, Jia YP, Wu J, Dong LJ, Chang LJ, Zhang LP. [Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi. 37: 115-118. PMID 27014980 DOI: 10.3760/Cma.J.Issn.0253-2727.2016.02.006 |
0.431 |
|
| 2016 |
Chang L, Dong L, Liu Y, Tsao S, Li Y, Liu L, Gao Z, Tan X, Lu D, Zhang J, Wang J, Ying Y, Zhang L, Zheng H, Wang K, et al. Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study Blood. 128: 587-587. DOI: 10.1182/Blood.V128.22.587.587 |
0.444 |
|
| 2016 |
Lai X, Liu J, Dong L, Ou-Yang H, Dian Z, Song J, Jiang Y, Yao X, Gu X, Gao X, Wu Y, Chang L. CD19 Epitope Escape after 4SCAR19 T Cell Therapy Resulted in Re-Establishment of Chemo-Sensitivity in Adult B-Cell Acute Lymphocytic Leukemia Patients Blood. 128: 1633-1633. DOI: 10.1182/Blood.V128.22.1633.1633 |
0.462 |
|
| 2016 |
Trinh TL, Wu Q, Chang L, Ho M, Liu C. Abstract 2316: GPC3-specific chimeric antigen receptor T cell in combination with Sorafenib as a novel therapeutic treatment for hepatocellular carcinoma Cancer Research. 76: 2316-2316. DOI: 10.1158/1538-7445.Am2016-2316 |
0.463 |
|
| 2016 |
Akbar MA, Cao JJ, Lu Y, Nardo D, Chen M, Elshikha AS, Ahamed R, Brantly M, Chang L, Holliday LS, Song S. 632. Alpha-1 Antitrypsin Gene Therapy Prevented Bone Loss in an Ovariectomy Induced Osteoporosis Mouse Model Molecular Therapy. 24: S250. DOI: 10.1016/S1525-0016(16)33440-2 |
0.31 |
|
| 2016 |
Chang L, Zhang J, Liu Y, Dong L, Wu T, Lu D. 195. Allogeneic CD19-CART Therapy to the Rescue of a Pediatric Patient with Relapsed and Refractory Acute B Lymphoblastic Leukemia Molecular Therapy. 24. DOI: 10.1016/S1525-0016(16)33004-0 |
0.437 |
|
| 2015 |
Ayed AO, Chang LJ, Moreb JS. Immunotherapy for multiple myeloma: Current status and future directions. Critical Reviews in Oncology/Hematology. PMID 26153389 DOI: 10.1016/J.Critrevonc.2015.06.006 |
0.393 |
|
| 2015 |
Okada S, Han S, Patel ES, Yang LJ, Chang LJ. STAT3 signaling contributes to the high effector activities of interleukin-15-derived dendritic cells. Immunology and Cell Biology. 93: 461-71. PMID 25582338 DOI: 10.1038/Icb.2014.103 |
0.331 |
|
| 2015 |
Niu T, Chang L, Yang J, Liu Y, Dong L, Wang W, Liu T. Rescue of a Terminally Ill Patient with Chemo-Refractory Acute Lymphoblastic Leukemia Carrying Bcr/Abl and TP53 Mutations Based on a 4th Generation CD19 Chimeric Antigen Receptor-Engineered T (CAR-T) Therapy Blood. 126: 5431-5431. DOI: 10.1182/Blood.V126.23.5431.5431 |
0.468 |
|
| 2015 |
Jing H, Chang L, Chen M, Bao F, Wang J, Wang W, Liu Y, Kuo H, Liu Y, Dong L. Up-Regulation of CAR-T Cells after G-CSF and Dexamethasone Treatment in a Defuse Large B Cell Lymphoma Patient Receiving 4SCAR19 T Cell Therapy Blood. 126: 5130-5130. DOI: 10.1182/Blood.V126.23.5130.5130 |
0.409 |
|
| 2015 |
Luo Y, Chang L, Hu Y, Dong L, Wei G, Huang H. First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia Blood. 126: 3778-3778. DOI: 10.1182/Blood.V126.23.3778.3778 |
0.49 |
|
| 2015 |
Dong L, Chang L, Gao Z, Lu D, Zhang J, Wang J, Zhang L, Chen Y, Zheng H, Liu T, Niu T, Huang H, Liu R, Wang H, Gao L, et al. Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China Blood. 126: 3774-3774. DOI: 10.1182/Blood.V126.23.3774.3774 |
0.442 |
|
| 2015 |
Chang L, Dong L, Zhu J, Ying Z, Kuo H, Liu Y, Song Y, Wang X, Jia Y, Niu T, Liu T, Pan L, Liu Z, Li T, Li Y, et al. 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass Blood. 126: 264-264. DOI: 10.1182/Blood.V126.23.264.264 |
0.474 |
|
| 2015 |
Chulanetra M, Sayour E, Eldjerou L, Lagmay J, Milner R, Slayton W, Chang L. Abstract 3157: Novel GD2-specific chimeric antigen receptor-modified T cells targeting osteosarcoma Cancer Research. 75: 3157-3157. DOI: 10.1158/1538-7445.Am2015-3157 |
0.492 |
|
| 2015 |
Sujjitjoon J, Atchaneeyasakul LS, Tsao S, Sayour E, Yenchitsomanus P, Chang L. Abstract 3150: GD2-specific chimeric antigen receptor T cells targeting retinoblastoma Cancer Research. 75: 3150-3150. DOI: 10.1158/1538-7445.Am2015-3150 |
0.474 |
|
| 2015 |
Chang L, Liu Y, Kuo H, Tsao S, Moreb JS. Abstract 3149: Chimeric antigen receptor-modified T cells against several target antigens in multiple myeloma Cancer Research. 75: 3149-3149. DOI: 10.1158/1538-7445.Am2015-3149 |
0.518 |
|
| 2015 |
Akbar MA, Lu Y, Chen M, Elshikha AS, Ahamed R, Brantly ML, Chang L, Holliday LS, Cao JJ, Song S. 508. Alpha-1 Antitrypsin (AAT) Gene and Stem Cell Based Therapies for the Treatment of Osteoporosis Molecular Therapy. 23: S203-S204. DOI: 10.1016/S1525-0016(16)34117-X |
0.324 |
|
| 2015 |
Ying Z, Chang L, Kuo H, Liu Y, Song Y, Wang X, Liu W, Zheng W, Xie Y, Lin N, Tu M, Ping L, Zhang C, Huang H, Zhu J. 415. First-In-Patient Proof of Safety and Efficacy of a 4th Generation Chimeric Antigen Receptor-Modified T Cells for the Treatment of Relapsed or Refractory CD30 Positive Lymphomas Molecular Therapy. 23: S164. DOI: 10.1016/S1525-0016(16)34024-2 |
0.445 |
|
| 2014 |
Chang L, Liu Y, Moreb JS. Abstract 2796: Engineering multiple chimeric antigen receptors in T cells for the treatment of multiple myeloma Cancer Research. 74: 2796-2796. DOI: 10.1158/1538-7445.Am2014-2796 |
0.499 |
|
| 2013 |
Wang Q, Wang H, Sun Y, Li SW, Donelan W, Chang LJ, Jin S, Terada N, Cheng H, Reeves WH, Yang LJ. The reprogrammed pancreatic progenitor-like intermediate state of hepatic cells is more susceptible to pancreatic beta cell differentiation. Journal of Cell Science. 126: 3638-48. PMID 23750005 DOI: 10.1242/Jcs.124925 |
0.414 |
|
| 2013 |
Bichsel C, Neeld D, Hamazaki T, Chang LJ, Yang LJ, Terada N, Jin S. Direct reprogramming of fibroblasts to myocytes via bacterial injection of MyoD protein. Cellular Reprogramming. 15: 117-25. PMID 23438194 DOI: 10.1089/Cell.2012.0058 |
0.326 |
|
| 2013 |
Cabrera R, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA, Chang LJ, Liu C, Nelson DR. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy : Cii. 62: 737-46. PMID 23223899 DOI: 10.1007/S00262-012-1380-8 |
0.31 |
|
| 2013 |
Moreb JS, Mona M, Chang L, Yeh Y, Amory J, Goldstein A. Abstract 3762: The role of aldehyde dehydrogenase isoenzymes in cancer cell proliferation, migration and drug resistance. Cancer Research. 73: 3762-3762. DOI: 10.1158/1538-7445.Am2013-3762 |
0.385 |
|
| 2012 |
Patel ES, Okada S, Hachey K, Yang LJ, Durum SK, Moreb JS, Chang LJ. Regulation of in vitro human T cell development through interleukin-7 deprivation and anti-CD3 stimulation. Bmc Immunology. 13: 46. PMID 22897934 DOI: 10.1186/1471-2172-13-46 |
0.464 |
|
| 2012 |
Patel ES, Chang LJ. Synergistic effects of interleukin-7 and pre-T cell receptor signaling in human T cell development. The Journal of Biological Chemistry. 287: 33826-35. PMID 22859301 DOI: 10.1074/Jbc.M112.380113 |
0.385 |
|
| 2012 |
Cuda CM, Li S, Liang S, Yin Y, Potula HH, Xu Z, Sengupta M, Chen Y, Butfiloski E, Baker H, Chang LJ, Dozmorov I, Sobel ES, Morel L. Pre-B cell leukemia homeobox 1 is associated with lupus susceptibility in mice and humans. Journal of Immunology (Baltimore, Md. : 1950). 188: 604-14. PMID 22180614 DOI: 10.4049/Jimmunol.1002362 |
0.391 |
|
| 2012 |
Yang L, Han S, Wang H, Markham M, Gray BA, Reeves W, Chang L. Characterization and Immunotherapeutic Implication of a Novel Cerebro-Spinal Fluid-Derived ALK-Positive Anaplastic Large Cell Lymphoma Cell Line Blood. 120: 5096-5096. DOI: 10.1182/Blood.V120.21.5096.5096 |
0.506 |
|
| 2012 |
Dong L, Gao Z, Yu X, Tan X, Liu J, Lu F, Xie Y, Chang L, Zhou L, Lu W, Tong C, Zeng Y, Hou S, Xu N, Yan X, et al. HLA Disparity Is Associated with Improved Outcomes in Hematological Malignancies After Family HLA-Mismatched /Haploidentical HCT but Not URD Blood. 120: 2014-2014. DOI: 10.1182/Blood.V120.21.2014.2014 |
0.316 |
|
| 2011 |
Bichsel C, Neeld DK, Hamazaki T, Wu D, Chang LJ, Yang L, Terada N, Jin S. Bacterial delivery of nuclear proteins into pluripotent and differentiated cells. Plos One. 6: e16465. PMID 21304583 DOI: 10.1371/Journal.Pone.0016465 |
0.368 |
|
| 2011 |
Chang L, Han S, Okada S, Patel E, Yang L, Moreb JS, Pircher H, Perez LE, Alsina M. Abstract LB-157: Overcoming T-regulatory effects towards developing a more effective immunotherapy targeting multiple myeloma Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-157 |
0.506 |
|
| 2011 |
Moreb JS, Ucar D, Han S, Ostmark B, Chang L. Abstract 4361: The enzymatic activity of aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance Cancer Research. 71: 4361-4361. DOI: 10.1158/1538-7445.Am2011-4361 |
0.375 |
|
| 2010 |
Han S, Wang Y, Wang B, Patel E, Okada S, Yang LJ, Moreb JS, Chang LJ. Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells from hematopoietic stem cells. Journal of Immune Based Therapies and Vaccines. 8: 8. PMID 21106069 DOI: 10.1186/1476-8518-8-8 |
0.368 |
|
| 2010 |
Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. Plos One. 5: e11726. PMID 20668510 DOI: 10.1371/Journal.Pone.0011726 |
0.493 |
|
| 2010 |
Li H, Lu Y, Witek RP, Chang LJ, Campbell-Thompson M, Jorgensen M, Petersen B, Song S. Ex vivo transduction and transplantation of bone marrow cells for liver gene delivery of alpha1-antitrypsin. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1553-8. PMID 20551917 DOI: 10.1038/Mt.2010.116 |
0.373 |
|
| 2010 |
Chang LJ. Lentiviral vector transduction of dendritic cells for novel vaccine strategies. Methods in Molecular Biology (Clifton, N.J.). 614: 161-71. PMID 20225043 DOI: 10.1007/978-1-60761-533-0_11 |
0.386 |
|
| 2010 |
Dong L, Gao ZY, Chang LJ, Liang Y, Tan XY, Liu JH, Yu XJ, Yang FH, Xie Y, Lu DP. Adoptive transfer of cytomegalovirus/Epstein-Barr virus-specific immune effector cells for therapeutic and preventive/preemptive treatment of pediatric allogeneic cell transplant recipients. Journal of Pediatric Hematology/Oncology. 32: e31-7. PMID 20051775 DOI: 10.1097/Mph.0B013E3181Bf5E2D |
0.376 |
|
| 2010 |
Moreb JS, Chang L, Han S, Ostmark B. Abstract 3362: Diethylaminobenzaldehyde (DEAB) is not a specific inhibitor of ALDH1a1 isozyme Cancer Research. 70: 3362-3362. DOI: 10.1158/1538-7445.Am10-3362 |
0.368 |
|
| 2009 |
Patel E, Wang B, Lien L, Wang Y, Yang LJ, Moreb JS, Chang LJ. Diverse T-cell differentiation potentials of human fetal thymus, fetal liver, cord blood and adult bone marrow CD34 cells on lentiviral Delta-like-1-modified mouse stromal cells. Immunology. 128: e497-505. PMID 19740310 DOI: 10.1111/J.1365-2567.2008.03013.X |
0.48 |
|
| 2009 |
Wang B, Han S, Lien L, Chang LJ. Lentiviral calnexin-modified dendritic cells promote expansion of high-avidity effector T cells with central memory phenotype. Immunology. 128: 43-57. PMID 19689735 DOI: 10.1111/J.1365-2567.2009.03067.X |
0.41 |
|
| 2009 |
Han S, Huang Y, Liang Y, Ho Y, Wang Y, Chang LJ. Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications. Journal of Hematology & Oncology. 2: 34. PMID 19660111 DOI: 10.1186/1756-8722-2-34 |
0.492 |
|
| 2009 |
Lin G, Wang G, Liu G, Yang LJ, Chang LJ, Lue TF, Lin CS. Treatment of type 1 diabetes with adipose tissue-derived stem cells expressing pancreatic duodenal homeobox 1. Stem Cells and Development. 18: 1399-406. PMID 19245309 DOI: 10.1089/Scd.2009.0010 |
0.34 |
|
| 2008 |
Moreb JS, Baker HV, Chang LJ, Amaya M, Lopez MC, Ostmark B, Chou W. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Molecular Cancer. 7: 87. PMID 19025616 DOI: 10.1186/1476-4598-7-87 |
0.349 |
|
| 2008 |
Han S, Wang B, Cotter MJ, Yang LJ, Zucali J, Moreb JS, Chang LJ. Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 269-79. PMID 18071334 DOI: 10.1038/Sj.Mt.6300369 |
0.466 |
|
| 2008 |
Chang L, Liang Y, Lien L, Tong CR, Dong L, Wu T, Fu Y, Yang F, Tang J, Lu D. Adoptive Immune Cell Therapy for the Control of Fungal Infections in Hematopoietic Stem Cell Transplant Patients Blood. 112: 4358-4358. DOI: 10.1182/Blood.V112.11.4358.4358 |
0.436 |
|
| 2008 |
Wu T, Tong C, Cao X, Wang J, Chang L, Liang Y, Lu D. Clinical Outcome of Aspergillus-Specific Cytotoxic T Lymphocytes for Refractory Invasive Aspergillosis in Patients with Hematological Malignancies. Blood. 112: 2215-2215. DOI: 10.1182/Blood.V112.11.2215.2215 |
0.356 |
|
| 2007 |
Cheng H, Wolfe SH, Valencia V, Qian K, Shen L, Phillips MI, Chang LJ, Zhang YC. Efficient and persistent transduction of exocrine and endocrine pancreas by adeno-associated virus type 8. Journal of Biomedical Science. 14: 585-94. PMID 17387636 DOI: 10.1007/S11373-007-9159-1 |
0.329 |
|
| 2007 |
Liang Y, Lien L, Han S, Tong C, Gao Z, Wu T, Tang J, Lu D, Chang L. Targeting Late Relapsed Acute Myeloid Leukemia Cells by Cytotoxic T Cells Generated from Late but Not Early Leukemic Antigen-Presenting Dendritic Cells. Blood. 110: 4902-4902. DOI: 10.1182/Blood.V110.11.4902.4902 |
0.479 |
|
| 2007 |
Chang L, Tong C, Tang J, Akatsuka Y, Han S, Liang Y, Li C, Dong L, Wu T, Lu D. Escape of Minor Histocompatibility Antigen-Restricted Anti-Leukemia Immunity Associated with Loss of Specific HLA-I Locus Expression in a Leukemia Patient after an Intensive Immunotherapy. Blood. 110: 4895-4895. DOI: 10.1182/Blood.V110.11.4895.4895 |
0.449 |
|
| 2006 |
Chen X, Wang B, Chang LJ. Induction of primary anti-HIV CD4 and CD8 T cell responses by dendritic cells transduced with self-inactivating lentiviral vectors. Cellular Immunology. 243: 10-8. PMID 17188256 DOI: 10.1016/J.Cellimm.2006.11.001 |
0.43 |
|
| 2006 |
Walton NM, Sutter BM, Chen HX, Chang LJ, Roper SN, Scheffler B, Steindler DA. Derivation and large-scale expansion of multipotent astroglial neural progenitors from adult human brain. Development (Cambridge, England). 133: 3671-81. PMID 16914491 DOI: 10.1242/Dev.02541 |
0.332 |
|
| 2006 |
Oka M, Chang LJ, Costantini F, Terada N. Lentiviral vector-mediated gene transfer in embryonic stem cells. Methods in Molecular Biology (Clifton, N.J.). 329: 273-81. PMID 16845997 DOI: 10.1385/1-59745-037-5:273 |
0.373 |
|
| 2006 |
Tang DQ, Cao LZ, Chou W, Shun L, Farag C, Atkinson MA, Li SW, Chang LJ, Yang LJ. Role of Pax4 in Pdx1-VP16-mediated liver-to-endocrine pancreas transdifferentiation. Laboratory Investigation; a Journal of Technical Methods and Pathology. 86: 829-41. PMID 16732298 DOI: 10.1038/Labinvest.3700434 |
0.375 |
|
| 2006 |
Tang DQ, Lu S, Sun YP, Rodrigues E, Chou W, Yang C, Cao LZ, Chang LJ, Yang LJ. Reprogramming liver-stem WB cells into functional insulin-producing cells by persistent expression of Pdx1- and Pdx1-VP16 mediated by lentiviral vectors. Laboratory Investigation; a Journal of Technical Methods and Pathology. 86: 83-93. PMID 16294197 DOI: 10.1038/Labinvest.3700368 |
0.394 |
|
| 2005 |
Chen X, Chang LJ. Mycoplasma-mediated alterations of in vitro generation and functions of human dendritic cells. Journal of Biomedical Science. 12: 31-46. PMID 15864737 DOI: 10.1007/S11373-004-8181-9 |
0.43 |
|
| 2005 |
Oka M, Meacham AM, Hamazaki T, Rodić N, Chang LJ, Terada N. De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2'-deoxycytidine. Oncogene. 24: 3091-9. PMID 15735669 DOI: 10.1038/Sj.Onc.1208540 |
0.356 |
|
| Show low-probability matches. |